- Home
- TOP vs NSRX Comparison
TOP vs NSRX Comparison
Compare TOP & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | NSRX |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | Singapore | Israel |
| Employees | N/A | 7 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 36.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TOP | NSRX |
|---|---|---|
| Price | $1.38 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 135.2K | 41.8K |
| Earning Date | 01-20-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $1.98 |
| 52 Week High | $3.33 | $9.99 |
Technical Indicators
Market Signals| Indicator | TOP | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 76.84 | 50.63 |
| Support Level | $0.98 | $2.78 |
| Resistance Level | $1.54 | $3.58 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 95.92 | 32.17 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.